O-[[2-butyl-5-chloro-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methyl]hydroxylamine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: O-[[2-butyl-5-chloro-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methyl]hydroxylamine
• 化学式: C₂₂H₂₄ClN₇O
• 分子量: 437.9
• InChiKey: PLMPWIKMWNSLPG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  31
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  108
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• Solid pharmaceutical composition comprising amlodipine and losartan
  申请人：HANMI PHARM. CO., LTD.

  公开号：US10034862B2

  公开（公告）日：2018-07-31

  The present invention provides a pharmaceutical composition for the prevention or treatment of cardiovascular disorders containing losartan or a pharmaceutically acceptable salt thereof; amlodipine or a pharmaceutically acceptable salt thereof; a disintegrant; and a coating agent. The composition of the present invention, which has the best combination and optimum ratio of a disintegrant to a coating agent, shows sufficient strength and high dissolution rates under various pH environments, and thus, it is useful for the preparation of an excellent solid formulation exhibiting improved drug delivery efficiency and storage stability.

  本发明提供了一种用于预防或治疗心血管疾病的药物组合物，其中含有洛沙坦或其药学上可接受的盐；氨氯地平或其药学上可接受的盐；崩解剂；以及包衣剂。 本发明的组合物具有崩解剂和包衣剂的最佳组合和最佳配比，在各种 pH 值环境下都能显示出足够的强度和较高的溶解速率，因此可用于制备具有更高的给药效率和储存稳定性的优良固体制剂。
• SOLID PHARMACEUTICAL COMPOSITION COMPRISING AMLODIPINE AND LOSARTAN
  申请人：HANMI PHARM. CO., LTD.

  公开号：US20170326110A1

  公开（公告）日：2017-11-16

  The present invention provides a pharmaceutical composition for the prevention or treatment of cardiovascular disorders containing losartan or a pharmaceutically acceptable salt thereof; amlodipine or a pharmaceutically acceptable salt thereof; a disintegrant; and a coating agent. The composition of the present invention, which has the best combination and optimum ratio of a disintegrant to a coating agent, shows sufficient strength and high dissolution rates under various pH environments, and thus, it is useful for the preparation of an excellent solid formulation exhibiting improved drug delivery efficiency and storage stability.
• [EN] SOLID PHARMACEUTICAL COMPOSITION COMPRISING AMLODIPINE AND LOSARTAN<br/>[FR] COMPOSITION PHARMACEUTIQUE SOLIDE COMPORTANT DE L'AMLODIPINE ET DU LOSARTAN
  申请人：HANMI PHARM IND CO LTD

  公开号：WO2016052866A1

  公开（公告）日：2016-04-07

  The present invention provides a pharmaceutical composition for the prevention or treatment of cardiovascular disorders containing losartan or a pharmaceutically acceptable salt thereof; amlodipine or a pharmaceutically acceptable salt thereof; a disintegrant; and a coating agent. The composition of the present invention, which has the best combination and optimum ratio of a disintegrant to a coating agent, shows sufficient strength and high dissolution rates under various pH environments, and thus, it is useful for the preparation of an excellent solid formulation exhibiting improved drug delivery efficiency and storage stability. Representative Drawing: Fig. 1